A lmost 5 million people are affected by heart failure (HF) in the United States with an incidence rate of 10 in 1000 for people aged >65 years. 1 The result of a primary cardiac insult and the syndrome of chronic HF is characterized by clinical symptoms, such as dyspnea, edema, and exercise intolerance. In addition, patients exhibit metabolic abnormalities, including cytokine activation, 2 insulin resistance, 3, 4 abnormal oxidative metabolism in skeletal muscle, and myocardium, 3, 5, 6 as well as impaired mitochondrial biogenesis 5, 7 leading to muscle atrophy with prognostic significance for patients with HF.
interleukin-1, and interleukin-6) in patients with chronic stable HF. 10 Furthermore, PUFAs increase the rate of muscle protein synthesis in older adults. 11 In addition, the amino acid glutamine is involved in maintaining a positive nitrogen balance by decreasing muscle proteolysis, as well as the synthesis of glutathione, an antioxidant. [12] [13] [14] In a recent study, amino acid supplementation in patients with HF improved exercise tolerance. 15 Although a combination of high protein and PUFA improves muscle function and decreases muscle wasting in murine models, 16 the effects of a combined glutamine and PUFA supplementation have not been tested in patients with HF.
We aimed to determine the effects of a combined glutamine and fish oil supplementation on skeletal muscle function and metabolism in patients with HF. For that purpose, we designed a randomized, prospective, double-blind, and placebo-controlled at our center. We hypothesized that the combined supplementation of high-dose ω-3 PUFAs and the dipeptide l-alanyl-l-glutamine improves both specific muscle functional parameters including muscle strength and fatigability and overall exercise tolerance in patients with HF. Secondary outcome measures included systemic and local markers of inflammation and metabolism including fatty acids and ceramides, as well as body anthromorphometry.
Methods

Patient Population and Study Design
In this a single-center, double-blind, placebo-controlled study, all subjects were recruited from the Columbia University Medical Center between October 18, 2011, and October 17, 2012, with follow-up until January 15, 2013. Patients aged >45 years with a left ventricular ejection fraction ≤35%, stable on standard HF medications, and on optimal therapy according to the American Heart Association and American College of Cardiology guidelines were eligible for this study. 17 Patients were excluded based on the following: major cardiovascular events or procedures in the past 6 months, dementia, or the presence of cardiovascular disease that may lead to harm if the patient took part in the study. Patients with congenital heart disease, long-QT syndrome, hypertrophic cardiomyopathy, or myocarditis were also excluded.
Patients were randomized to either a combination of 8 g/d lalanyl-l-glutamine and 6.5 g/d fish oil or to a combination of safflower oil and milk powder (placebo) of equivalent caloric intake. The study compounds were provided blinded and randomized by Natural Organic laboratories, Inc, in cooperation with Barlean's Organic Oils & Company.
Patients were evaluated at baseline and at 1 and 3 months, and clinical and laboratory data were collected from electronic medical records. At all study visits, complete clinical evaluations, quality-oflife (Qol) questionnaires, a 6-minute walk test, handgrip strength test, muscle testing by Biodex testing, and blood draw were performed. A cardiopulmonary exercise test, dual-energy x-ray absorptiometry scan, and echocardiography in all subjects and a voluntary muscle biopsy in a subset of patients were performed at study visit 1 and 3.
The primary end point of this study was changes in exercise function assessed by cardiopulmonary exercise test, 6-minute walk test, and muscle functional testing. Secondary end points included skeletal muscle metabolism, echocardiography, and inflammatory serum markers. Group size was calculated based on a previous study using ω-3 PUFA supplementation in patients with HF 10 and institutional reference data in our cohort of patients with advanced HF. On the basis of a baseline average VO 2 max of 15 ml/min per kilogram (SD, 3 ml/min per kilogram) and an expected meaningful increase of 20% to 18 ml/min per kilogram with 80% power and α<0.05, a minimal group size of 11 subjects was calculated. This was confirmed by a baseline average 6-minute walk test of 365 m (SD, 45 m) and an expected meaningful increase of at least 10% to 400 m; the minimal group size was calculated as 11 subjects for 80% power and α<0.05. To account for attrition, we added a 25% increase and aimed to recruit at least 15 subjects per group.
The study protocol was approved by the Columbia University Medical Center Institutional Review Board, and written informed consent was obtained from each patient before study inclusion.
Assessment of Quality of Life
The Kansas City Cardiomyopathy Questionnaire 18 and Minnesota living with HF 19 questionnaires were used to evaluate all patients.
Echocardiographic Analysis
Conventional echocardiograms were obtained from all patients at study visit 1 and 3 (Sonos-5500 or Sonos-7500; Philips Healthcare, Andover, MA). The routine standard echocardiographic examination included M-mode, 2-dimensional echocardiogram, and Doppler study for measurements of ventricular septal and posterior wall thickness and end-systolic and end-diastolic lV diameters. The lV ejection fraction was calculated by biplane Simpson method from apical 4-and 2-chamber views. Mitral inflow was obtained by pulsed-wave Doppler echocardiography with the sample volume between mitral leaflet tips during diastole, peak early (E) and late (A) transmitral filling velocities, and their ratio (E/A), and deceleration time of E was measured. The peak positive dP/dt (dP/dt max , first derivative of lV pressure with respect to time) as an index of contractility was calculated based on continuous wave Doppler determination of the velocities in mitral regurgitant jets. Early diastolic annular velocity (E′) was obtained by placing a tissue Doppler sample volume at the septal and lateral mitral annulus in the apical 4-chamber view, and the E/E′ ratio was calculated. Measurements were performed from 5 cardiac cycles and averaged.
Cardiopulmonary Exercise Testing
Patients were subjected to cardiopulmonary exercise testing using an incremental biking exercise performed on a bicycle ergometer (Ergometrics 800; SensorMedics Inc, Yorba linda, CA). Subjects were instructed to maintain a pedal speed of 60 revolutions/min with linear increase in resistance each minute. Once the workload became too high and the patient could no longer maintain 60 revolutions/min, the test was stopped and patients subsequently performed 3 minutes of active recovery. Peak effort oxygen consumption (VO 2 max), rate of perceived exertion, blood pressure, and heart rate were all measured throughout the testing exercise.
Six-Minute Walking Distance
Subjects were instructed to walk as fast as possible over a period of 6 minutes. The test was scored by rounded meters walked in 6 minutes.
Hand Grip Strength Testing
Hand grip strength was measured using a Jamar hand dynamometer (Sammons Preston Inc, Boiling Brook, Il). Subjects were asked to 2 subjects dropped out 12 subjects completed the study 3 subjects dropped out 14 subjects completed the study 17 subjects enrolled in active group 14 subjects enrolled in placebo group 204 patients screened 31 subjects randomized Figure 1 . Study design and enrollment.
perform a maximal isometric contraction with each hand for 3 consecutive times. Each contraction was followed by a 5-second rest period. Averages for each hand were taken. Hand grip strength was normalized for total body weight (BW).
Muscle Function Testing
Muscle functional testing was performed by trained staff under the supervision of a physician. Biodex System 4 Pro (Biodex Medical Systems, Shirley, NY) was used to measure both isometric and isokinetic movements. The dominant knee was first test followed by the dominant elbow. For isometric contractions, subjects contracted against a constant 60° angle at the knee and a constant 30° angle at the elbow for 6 seconds. Subjects alternated between flexion and extension, 3 repetitions each with a 30-second rest period between each. Data were collected to determine peak torque to BW.
For isokinetic contractions, subjects performed flexion and extension movements at the knee and elbow for 5 repetitions at a speed of 60°/second. This was followed by a rest period of 2.5 minutes. For the second isokinetic protocol, subjects performed 25 repetitions of flexion and extension movements at the knee and elbow at a speed of 180°/s. Data were collected to determine peak torque/BW, average power, work to BW, fatigability, and time to peak torque. Normalization of the data to BW allowed for a more meaningful comparison of measurements among subjects.
Dual-Energy X-ray Absorptiometry
Bone mass, lean mass, fat mass, and body composition were measured by dual-energy x-ray absorptiometry using established protocols.
Blood Collection and Analysis
Venous blood samples were drawn at all study visits. The blood was collected in two 8.5-ml SST tubes and two 7.0-ml EDTA tubes.
Samples were subsequently spun for 20 minutes at 2500 rpm at 4°C. Aliquots of 500-μl serum and plasma were pipetted into cryovials and frozen at −80°C. levels of tumor necrosis factor-α were measured with a commercially available ElISA kit (R&D Systems, Minneapolis, MN).
Liquid Chromatography-Mass Spectrometry
All solvents for sample extraction and liquid ChromatographyMass Spectrometry (lC/MS) were lC/MS grade (or lC grade when lC/MS grade was not available) and were purchased from Fisher Scientific (Pittsburgh, PA). Standards were purchased from Avanti Polar lipid, Inc (Alabaster, Al).
Samples were extracted using chloroform:methanol extraction. Briefly, 3 ml of the chloroform:methanol (2/1, v/v) containing 20 μl of a 2-μmol/l internal standard mixture (Avanti lM-6002, containing C12 and C25 ceramides) were added to 100-μl aqueous of tissue or cell homogenate in a clean glass tube. The mixture was vortexed well. A volume of 0.5 ml of water was added to the mixture to allow for phase separation. The mixture was vortexed again and centrifuged at 3000g for 10 minutes. The lower organic phase was transferred to a second clean glass tube using a Pasteur pipette. A volume of 2 ml of chloroform were added to the residual aqueous phase, followed by vortex mixing and centrifugation again at 3000g for 10 minutes, to extract the remaining lipids. The lower organic phases were pooled and evaporated under nitrogen. The extracted lipids were reconstituted in 30 μl of methanol and transferred to lC/MS autosampler vials (Waters, P/N 600000670CV) for injection.
All experiments were performed on a Waters Xevo TQ MS ACQUITY UPlC system (Waters, Milford, MA). The system was controlled by Mass lynx Software version 4.1. The sample was maintained at 4°C in the autosampler, and 5 μl was loaded onto a Waters ACQUITY UPlC BEH Phenyl column (3-mm inner diameter×100 mm with 1.7-μm particles), preceded by a 2.1×5 mm guard column containing the same packing. The column was maintained at 40°C throughout analysis. The UPlC flow rate was continuously 300 μl/ min in a binary gradient mode with the following mobile phase: initial flow conditions were 20% solvent A (H 2 O, containing 0.2% formic acid and 1 mmol/l ammonium formate) and 80% solvent B (methanol, containing 0.2% formic acid and 10 mmol/l ammonium formate).
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Analysis of Amino Acids
Plasma amino acids were measured by high-performance liquid chromatography-UV (Alliance 2695 high-performance liquid chromatography/2487 Dual Absorbance Detector; Waters Corp). In brief, after the addition of the internal standard (methionine sulfone; Sigma), plasma was stripped of protein by size exclusion filtration (Amicon Ultra 0.5-ml centrifuge filter 10 KD; EMD Millipore), derivatized with an amino-specific chromogen (phenyl isothiocyanate; Sigma) and passed through a C18-high-performance liquid chromatography column for amino acid separation (Pico-Tag Column, 60 Å, 4 µm, 3.9 mm×300 mm) with a detection wavelength 254 nmol/l. Endogenous concentrations of amino acids were calculated relative to a 1-point calibrator and normalized to the area of an internal standard.
Muscle Biopsy
Voluntary percutaneous muscle biopsies of the vastus lateralis muscle of the nondominant leg were performed in a subset of patients using a Bergstrom needle 15 cm above the patella. Specimens were taken before and after the trial period and dissected free of visible connective tissue and fat. The muscle tissue was either immediately frozen in liquid nitrogen and stored at -80°C or fixed in paraformaldehyde.
Histomorphometric Analysis
Muscle fiber cross-sectional area were analyzed on muscle biopsies obtained at the beginning and at the end of the study using previously described methods. In short, hematoxylin-eosin-stained sections (5 µm) were reviewed microscopically at ×10 magnification (Nikon Eclipse E 200), and fiber size was analyzed using standard imageprocessing software (NIH ImageJ). For all slides, the scale was set to 2.84 pixels/unit based on a standardized stage micrometer for ×10 magnification. Frequency histograms were constructed based on the number of muscle fibers falling within cross-sectional area groups.
Immunohistochemistry was performed for the characterization of muscle fiber oxidative quality and fiber typing. Paraffinembedded sections (5 µm) were first incubated in 5% goat serum to reduce nonspecific immunoreactivity and subsequently with primary antimyosin antibodies (monoclonal antifast twitch skeletal muscle myosin, 1:400; Sigma). Specific immunoreactivity was detected with a secondary rabbit antimouse antibody (1:400; Pierce) followed by conjugation with avidin-biotin complex (ABC Kit; Pierce). Immunopositive fibers were quantified and expressed as percent of all muscle fibers. 
Gene Expression Analysis
Total RNA was extracted using standard methods, and the abundance of specific mRNAs was determined by reverse transcriptase polymerase chain reaction. Sequences of primers and TaqMan probes specific for PGC1α, CPT1, PDK4, GlUT4 were described previously. [21] [22] [23] [24] Gene expression was normalized using expression of 18S mRNA and expressed as relative expression.
Fatty Acid Oxidation
Thirty milligram of muscle tissue was analyzed as previously described 25 with slight modifications. Specimens were placed in flask containing 1-ml low-glucose DMEM cell culture medium (Cellgro), 1.5% delipidated BSA (Sigma), 0.2 mmol/l oleic acid, 1 βµCi/ml (14C) oleic acid, cup with rubber stoppers that had been inserted a cell holding a rolled filter paper and incubated at 37°C for 2 hours. The filter papers were soaked with 1 N KOH, and the reaction was stopped injecting 200 μl of 70% perchloric acid and incubating for 1 hour with shaking. At the end of the incubation, the filter papers were transferred to vials containing scintillation liquid and counts per minute were measured using a scintillation liquid counter machine. The total fatty acid oxidation reaction rate was evaluated as CO 2 produced and analyzed from counts per minute in the filter papers.
Statistical Analysis
Data were analyzed using GraphPad Prism, version 5.0b (San Diego, CA) and are presented as mean±SEM. For categorical variables, results are presented as relative frequency. Normality was evaluated for each variable by the Kolmogorov-Smirnov test. Serial values within the 2 treatment groups were assessed using Student paired t test or Wilcoxon signed-rank test. Unpaired analyses were completed when comparing between the 2 treatment groups using unpaired Student t test or Mann-Whitney test. All tests were 2 tailed. Differences among 3 time points (baseline, 1 month, and 3 months) were analyzed using 1-way ANOVA (parametric) or the KruskalWallis test because of missing data points because of patient dropouts within the groups at 1 month and 3 months. Tukey and Dunn multiple comparison post hoc tests were used. A P value of <0.05 was considered statistically significant, and no adjustments were made for the multiplicity of comparisons.
Results
Patient Demographics and Laboratory Parameters
Of 31 patients enrolled in the study, 17 subjects were randomized to the active treatment group and 14 to the placebo group. Of these, 3 subjects dropped out in the active treatment group (1 because of diarrhea at 2 weeks, and 2 patients were lost to follow-up), and 2 dropped out of the placebo group (both because of diarrhea at 2 and 6 weeks). A total of 14 subjects finished the study protocol in the active treatment group and 12 in the placebo group (Figure 1) . Clinical characteristics Right ventricular E/E′ 10.3±0.5 9.5±0.9 9.7±1.1 11.0±0.6 9.3±0.6
Post represents 3 mo after the intervention. Values are expressed at mean±SEM. A indicates peak late transmitral filling velocity; E, peak early transmitral filling velocity (E); E′, early diastolic annular velocity; and LV, left ventricular.
of all patients at baseline and at 3-month follow-up are summarized in Table 1 . laboratory parameters at baseline and at 3-month follow-up are listed in Table 2 . No difference in change (baseline to 3 months) in body mass index or blood pressure were noted between groups. Supplementation with l-alanyl-l-glutamine and PUFAs showed a trend toward a decrease in triglyceride levels but did not affect circulating levels of tumor necrosis factor α.
Exercise Parameters
No changes in any of the exercise parameters analyzed in the current study were noted. Cardiopulmonary exercise test revealed no differences from baseline to 3 months in VO 2 max in neither the active treatment nor the placebo group (7.9±4.7 versus 0.1±0.7% change in VO 2 max in placebo; P=0.26). Sixminute walk test and handgrip strength corrected for BW also did not show any changes under treatment (Figure 2) . Analysis of specific parameters of isolated leg and arm skeletal muscle function did not reveal differences in response to l-alanyll-glutamine and PUFA supplementation when compared with that in response to placebo (Table 3; Tables I-IV in the Data  Supplement) .
Echocardiography
Comprehensive analysis of markers of both left and right ventricular systolic and diastolic functions showed no differences in any of the parameters between both groups (Table 4) .
Quality of Life
The 2 Qol questionnaires used in this study showed a consistent improvement in Qol of patients with HF in the active treatment group. Using the Kansas City Cardiomyopathy Questionnaire, a significant overall improvement was found (73±19-83±12; P=0.04) accompanied by improved social limitation scores (72±24-86±15; P=0.006) and overall Qol (62±27-75±16; P=0.04) as expressed in absolute values. This was paralleled by improvements in the Minnesota living With Heart Failure scores in the active treatment group when compared with Minnesota living With Heart Failure scores in the placebo (36±22-24±16; P=0.02; Figure 3 ).
Body Anthromorphometry
No changes in body mass index were noted between the treatment groups. Using dual-energy x-ray absorptiometry scanning, a slight but statistically significant increase in absolute lean body mass (54.4±2. 8 
Analysis of Skeletal Muscle Histomorphometry and Metabolism
We analyzed skeletal muscle metabolic and histological parameters in a subset of 9 patients who underwent skeletal muscle biopsy at baseline and at 3-month follow-up (4 patients in the active treatment group and 5 patients in the placebo group). The analysis of muscle fiber cross-sectional area, myosin immunohistochemistry, and fiber typing did not reveal significant differences between the 2 groups. Furthermore, no differences in skeletal muscle fatty acid oxidation rates or expression of metabolic marker genes were noted ( Figure 5 ).
Lipidomic Analysis of Circulating Fatty Acids and Ceramides
Using lC/MS lipidomics, we analyzed the circulating profile of fatty acids in both groups. No differences in total fatty acids between baseline and 3-month follow-up between the 2 groups were noted ( Figure 6 ). Next, this analysis revealed the expected increase in unsaturated fatty acids (C20:1, C20:5, C22:1, C22:6, and C24:1) in the active treatment group (Figure 6A and 6B) , confirming the regular uptake of the study compounds by the patients in this group and a distinct 
Amino Acid Analysis
Using MS, we analyzed circulating amino acids in both groups. We did not observe any differences in circulating amino acids between baseline and follow-up within or between the 2 groups (Table VII in the Data Supplement ). Although not significant, the active treatment group did have higher levels of circulating glutamine after 3 months of treatment, whereas the placebo group did not (511±21-530±28 µmol/l and 528±16-510±36 µmol/l, respectively; P=NS). Of note, the downstream metabolites of glutamine metabolism, citrulline, and arginine did not change after 3 months of treatment in either group (citrulline, 39.4±3.9-34.0±3. 
Discussion
The current study demonstrates that the combined supplementation of l-alanyl-l-glutamine and PUFA does not improve exercise performance or muscle function or markers of systemic inflammation or peripheral skeletal muscle structure or metabolism in patients with advanced HF. We found, however, an increased lean body mass and improved Qol in patients with advanced HF in the treatment group. These findings suggest that the combined supplementation of l-alanyll-glutamine and PUFA may improve subjective parameters of Qol and may improve body composition in patients with advanced HF. The syndrome of HF is associated with high morbidity and mortality that have been linked to the progressive development of metabolic abnormalities, inflammation, and atrophy in the myocardium and the skeletal muscle in these patients. In patients with advanced HF, a distinct metabolic switch from fatty acids to glucose as the principal energy substrate for ATP generation occurs in the myocardium. It is hypothesized that the switch is the result of a regression to the fetal gene program, with decreased expression of carnitine palmitoyltransferase-1, medium chain acyl-CoA dehydrogenase, and citrate synthase. This may then account for mitochondrial dysfunction and ultimately, a preferential flux through the glycolytic pathway. Interestingly, this metabolic switch is also seen in skeletal muscle with increased type II glycolytic muscle fibers and decreased type I oxidative fibers. This intrinsic metabolic defect in skeletal muscle is thought to contribute to exercise intolerance, but therapeutic interventions improving peripheral skeletal muscle function are lacking. Therefore, nutritional approaches with dietary supplementation in addition to current pharmacological therapies are particularly appealing as they are novel and mechanistically different.
Fish oil contains a large amount of PUFAs and has been shown to be cardioprotective and anti-inflammatory. PUFA supplementation reduced mortality in a large study of patients with HF and has been shown to carry anti-inflammatory properties and improve ventricular function in HF. 9, 10 The cellular pathways of PUFA action are still uncertain, but it is thought that the double bounds of eicosapentaenoic acid and docosahexaenoic acid may act directly or through metabolites such as eicosanoids as scavengers of ROS. 26 Furthermore, PUFAs have been shown to have antifibrotic effects in the failing myocardium 27 and can reverse lipotoxicity in animal models of human metabolic cardiomyopathies 28 proposed to be mediated through membrane stabilization, improved mitochondrial function, and higher ATP production. 26 Nutritional supplementation with glutamine or its amino acid metabolites is of particular interest in catabolic states such as HF. Glutamine is an amino acid largely produced by the skeletal muscle and liver and accounts for the majority of carbon and nitrogen metabolism in the cell. 29 Glutamine has also been shown to attenuate inflammation, especially in the critically ill. 13 Glutamine attenuates skeletal muscle proteolysis, can replete intermediates in the tricarboxylic acid (TCA) cycle through anaplerosis, and might activate the suppressed oxidative metabolism in HF. 16, 29, 30 The predominant anaplerotic reaction in exercising human muscle is regulated by alanine aminotransferase, an enzyme that catalyzes the conversion between pyruvate and glutamate and alanine and α-ketoglutarate. 29, 30 Previous studies found that replenishing TCA cycle intermediates with pyruvate or glutamine acutely increased flux through the TCA cycle and suggests improved oxidative metabolism and ATP production. 31 Of note, anaplerotic flux might play a more important role than the total concentration of TCA cycle intermediates in determining the overall TCA flux. Nevertheless, our study did reveal changes in fatty acid oxidation rates or metabolic gene expression in skeletal muscle between the 2 groups.
Most studies using glutamine supplementation have been completed in acute settings, where it is infused and testing is done within minutes or after a bout of exercise. Some authors think that early metabolic support can improve the myocardial recovery in response to ischemia. When myocardial infarction was induced in rats, those reperfused with glutamine showed a significant recovery of cardiac output and no decrease in the ATP/ADP ratio when compared with those reperfused with aspartate and glutamate,. 32 However, ingestion of glutamine before exercise might only augment the pool of TCA cycle intermediates but neither increase TCA cycle flux nor extend endurance capacity. The contribution to anaplerosis in skeletal muscle has not been studied.
Increased amino acid intake in elderly sedentary subjects results in higher ambulatory capacity and maximal isometric muscle strength. 33 A 30-day amino acid supplementation (4 g twice daily) in elderly patients with HF improved exercise capacity, reduced circulatory dysfunction, and increased peripheral oxygen availability. 34 This was associated with increased peak VO 2 , a shorter recovery time, and improved peripheral metabolism, suggesting that a high protein and essential amino acid diet may improve markers of nutrition and exercise performance in patients with HF. 35 This was confirmed in a randomized single-blind crossover study in patients with type 2 diabetes mellitus on a 12-week amino acid supplementation (12 g/d) also showing improved exercise performance. 36 In our study, however, we did not detect differences in exercise performance or plasma amino acid levels, but found a small, but significant, increase in total lean body mass in the active treatment group. This small increase in total lean mass may suggest an increased activity level and thus improved Qol for the active treatment group, but further analysis is needed.
Our current study used a distinct form of glutamine, l-alanyl-l-glutamine, a dipeptide of l-alanine and l-glutamine. This formulation is highly soluble and more stable than glutamine. Furthermore, it increases the enteric uptake of glutamine and increases plasma half-life. 37 Previous studies have shown beneficial effects of the use of l-alanyl-l-glutamine when compared with the use of glutamine alone in critically ill patients, 38 after vascular surgery, 39 and in animal models of ischemia and reperfusion, 40 as well as endurance exercise. 41 Because of its high solubility, the dipeptide was administered together with the fish oil formulation as a combined study compound.
Another unique aspect of our study design was the high concentration of fish oil and glutamine in our study. A dose of 6.5 g/d of fishoil and 8 g/d of glutamine accounted for ≈400 kcal additional nutritional intake per day. To avoid effects of caloric supplementation alone in a patient cohort known to develop a progressive catabolic state, we controlled for equal caloric intake using a placebo formulation based on safflower oil and milk powder. Of note, the placebo formula has similar total fat, carbohydrate content, and protein content as the active supplementation.
Additional studies will analyze the effects of glutamine and fish oil potentially in combination with other micronutrients in patients with HF to better discern the actions of these nutritional supplements and their therapeutic utility in patients with HF. A search for the metabolic mechanisms will provide stronger evidence for our initial hypothesis. The working hypothesis that anti-inflammatory and proanabolic interventions will positively affect the clinical status of patients with chronic inflammatory disease states is applicable to other conditions such as rheumatoid arthritis, chronic kidney disease, or cancer.
Our study has several limitations. The analysis represents a single-center study with a selected patient cohort. The cohort is predominantly men, but had a high proportion of blacks and Hispanics. Muscle biopsies were taken only from volunteers and represent only a subgroup in this study. We did not analyze amino acid metabolism or pools in circulation or skeletal muscle.
A B
Total Ceramide In summary, we show beneficial effects of l-alanyl-l-glutamine and PUFAs on Qol and body compositions but a lack of effects on exercise performance, markers of inflammation, and cardiac structure or performance in this single-center, randomized, and blinded study. These findings suggest only mild-to-modest benefits of nutritional supplementation using glutamine and PUFAs in patients with HF.
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